Immunovant Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2019 | $-450 | $-450 | — | — |
| Jun 2019 | $-8.3M | $-8.3M | $0 | $572.0K |
| Sep 2019 | $-17.6M | $-17.6M | $8.0K | $3.1M |
| Dec 2019 | $-4.4M | $-4.4M | $13.0K | $1.4M |
| Mar 2020 | $-23.1M | $-23.1M | $10.0K | $1.8M |
| Jun 2020 | $-13.8M | $-13.8M | $47.0K | $4.0M |
| Sep 2020 | $-24.2M | $-24.3M | $39.0K | $3.4M |
| Dec 2020 | $-22.8M | $-22.8M | $29.0K | $6.0M |
| Mar 2021 | $-22.5M | $-22.6M | $95.0K | $5.5M |
| Jun 2021 | $-21.2M | $-21.2M | $18.0K | $3.9M |
| Sep 2021 | $-20.0M | $-20.1M | $44.0K | $8.4M |
| Dec 2021 | $-31.9M | $-32.0M | $74.0K | $10.2M |
| Mar 2022 | $-33.0M | $-33.1M | $118.0K | $11.9M |
| Jun 2022 | $-65.8M | $-65.9M | $42.0K | $7.7M |
| Sep 2022 | $-20.2M | $-20.2M | $31.0K | $8.2M |
| Dec 2022 | $-46.4M | $-46.5M | $98.0K | $8.9M |
| Mar 2023 | $-55.8M | $-55.8M | $26.0K | $7.5M |
| Jun 2023 | $-47.4M | $-47.4M | $45.0K | $10.7M |
| Sep 2023 | $-60.1M | $-60.1M | $34.0K | $10.5M |
| Dec 2023 | $-47.1M | $-47.2M | $131.0K | $10.2M |
| Mar 2024 | $-59.7M | $-59.8M | $150.0K | $9.7M |
| Jun 2024 | $-76.2M | $-76.4M | $182.0K | $13.5M |
| Sep 2024 | $-88.6M | $-88.8M | $196.0K | $12.7M |
| Dec 2024 | $-100.4M | $-100.6M | $180.0K | $11.7M |
| Mar 2025 | $-110.6M | $-110.8M | $201.0K | $11.7M |
| Jun 2025 | $-117.4M | $-117.4M | $0 | $18.5M |
| Sep 2025 | $-102.5M | $-102.5M | $0 | $13.4M |
| Dec 2025 | $-92.3M | $-92.3M | $0 | $12.7M |
| Mar 2026 | $-95.1M | $-95.1M | $8.0K | $11.1M |
| Jun 2026 | $-124.4M | $-124.4M | — | $13.8M |